<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2024/09/aa35c3157b628a248aaf3d8225487158.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2024/09/aa35c3157b628a248aaf3d8225487158.jpg"/></p>
<p>TransMedics 集团股票（NASDAQ：TMDX）在发布 2023 年第三季度财报后经历了显著的股价下跌。公司股价暴跌超过 25％，这一反应被归因于低于预期的营收和利润数据。</p>
<p>以其创新器官移植技术而闻名的 TransMedics 报告称，该季度营收为 4200 万美元，低于分析师对 4500 万美元的预期。该季度净亏损为 750 万美元，而去年同期净收入为 200 万美元。财务表现的 drastical 变化引发了投资者对公司未来增长轨迹和盈利能力的担忧。</p>
<p>导致营收不及预期的关键因素之一是 TransMedics 的器官护理系统（OCS）技术的采用速度低于预期。尽管 OCS 被誉为器官保存和移植的开创性解决方案，但其融入临床实践面临了诸多障碍，包括监管挑战和来自传统保存方法的竞争。</p>
<p>此外，公司的运营成本激增，主要是由于加大了用于推广 OCS 技术的研发和营销支出。这些支出给公司的底线带来了额外压力，加剧了营收不及预期的影响。</p>
<p>TransMedics 首席执行官 Waleed Hassanein 博士在财报电话会议中回应了这些担忧，强调了公司的长期愿景和克服当前障碍的承诺。他强调了扩大全球使用 OCS 技术的持续举措，并向投资者保证公司致力于在关键市场获得监管批准。</p>
<p>尽管存在即时的财务挫折，一些分析师对 TransMedics 未来前景持乐观态度。他们指出器官移植需求增长以及 OCS 技术革新该领域的潜力作为可能推动公司长期成功的因素。然而，他们也警告称，通往广泛采用和盈利的道路可能比最初预期的更漫长和更具挑战性。</p>
<p>总之，TransMedics 股价最近的暴跌凸显了生物技术行业的波动性，公司往往面临重大的财务和运营挑战。尽管公司的创新技术具有潜力，但其在规管环境中航行并实现商业成功的能力将对其未来表现至关重要。</p>
<p><strong>脚注：</strong></p>
<p>特色图片：DepositPhotos @ Capifrutta</p>
<p>免责声明</p>
<p>本文转载自 Invezz</p>

TMDX

<p>TransMedics 集团公司（NASDAQ：TMDX）发布了 2023 年第三季度财报，营收和利润均未达到预期，导致股价下跌超过 25%。公司报告的营收显著低于分析师预测，并出现了与去年相比的净亏损。器官护理系统的采用挑战和运营成本上升导致了这一下滑。尽管引发了一些担忧，但一些分析师仍对未来增长持乐观态度，因为器官移植需求不断增加</p>

<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2024/09/aa35c3157b628a248aaf3d8225487158.jpg" alt="" original-src="https://ik.imagekit.io/invezz/uploads/2024/09/aa35c3157b628a248aaf3d8225487158.jpg"/></p>
<p>TransMedics Group Inc. (NASDAQ:TMDX) experienced a significant drop in its stock price following the release of its Q3 2023 earnings report. The company’s stock plummeted by over 25%, a reaction attributed to the lower-than-expected revenue and profit figures.</p>
<div class="lb-trans"><p>TransMedics 集团股票（NASDAQ：TMDX）在发布 2023 年第三季度财报后经历了显著的股价下跌。公司股价暴跌超过 25％，这一反应被归因于低于预期的营收和利润数据。</p>
</div><p>TransMedics, renowned for its innovative organ transplant technologies, reported revenues of $42 million for the quarter, which fell short of analysts’ expectations of $45 million. The net loss for the quarter was reported at $7.5 million, compared to a net income of $2 million in the same period last year. This drastic change in financial performance raised concerns among investors about the company’s growth trajectory and profitability in the near future.</p>
<div class="lb-trans"><p>以其创新器官移植技术而闻名的 TransMedics 报告称，该季度营收为 4200 万美元，低于分析师对 4500 万美元的预期。该季度净亏损为 750 万美元，而去年同期净收入为 200 万美元。财务表现的 drastical 变化引发了投资者对公司未来增长轨迹和盈利能力的担忧。</p>
</div><p>One of the key factors contributing to the revenue shortfall was the slower-than-anticipated adoption of TransMedics’ Organ Care System (OCS) technology. While the OCS has been touted as a groundbreaking solution for organ preservation and transplantation, its integration into clinical practice has faced several hurdles, including regulatory challenges and competition from established preservation methods.</p>
<div class="lb-trans"><p>导致营收不及预期的关键因素之一是 TransMedics 的器官护理系统（OCS）技术的采用速度低于预期。尽管 OCS 被誉为器官保存和移植的开创性解决方案，但其融入临床实践面临了诸多障碍，包括监管挑战和来自传统保存方法的竞争。</p>
</div><p>Furthermore, the company’s operational costs have surged, primarily due to increased spending on research and development (R&amp;D) and marketing efforts aimed at promoting the OCS technology. These expenses have put additional pressure on the company’s bottom line, exacerbating the impact of the revenue miss.</p>
<div class="lb-trans"><p>此外，公司的运营成本激增，主要是由于加大了用于推广 OCS 技术的研发和营销支出。这些支出给公司的底线带来了额外压力，加剧了营收不及预期的影响。</p>
</div><p>TransMedics’ CEO, Dr. Waleed Hassanein, addressed these concerns during the earnings call, emphasizing the company’s long-term vision and commitment to overcoming the current obstacles. He highlighted ongoing initiatives to expand the use of OCS technology globally and assured investors of the company’s dedication to achieving regulatory approvals in key markets.</p>
<div class="lb-trans"><p>TransMedics 首席执行官 Waleed Hassanein 博士在财报电话会议中回应了这些担忧，强调了公司的长期愿景和克服当前障碍的承诺。他强调了扩大全球使用 OCS 技术的持续举措，并向投资者保证公司致力于在关键市场获得监管批准。</p>
</div><p>Despite the immediate financial setbacks, some analysts remain optimistic about TransMedics’ future prospects. They point to the growing demand for organ transplants and the potential for OCS technology to revolutionize the field as factors that could drive the company’s success in the long run. However, they also caution that the path to widespread adoption and profitability may be longer and more challenging than initially anticipated.</p>
<div class="lb-trans"><p>尽管存在即时的财务挫折，一些分析师对 TransMedics 未来前景持乐观态度。他们指出器官移植需求增长以及 OCS 技术革新该领域的潜力作为可能推动公司长期成功的因素。然而，他们也警告称，通往广泛采用和盈利的道路可能比最初预期的更漫长和更具挑战性。</p>
</div><p>In conclusion, the recent plunge in TransMedics’ stock price underscores the volatile nature of the biotech sector, where companies often face significant financial and operational challenges. While the company’s innovative technology holds promise, its ability to navigate regulatory landscapes and achieve commercial success will be crucial in determining its future performance.</p>
<div class="lb-trans"><p>总之，TransMedics 股价最近的暴跌凸显了生物技术行业的波动性，公司往往面临重大的财务和运营挑战。尽管公司的创新技术具有潜力，但其在规管环境中航行并实现商业成功的能力将对其未来表现至关重要。</p>
</div><p><strong>Footnotes:</strong></p>
<div class="lb-trans"><p><strong>脚注：</strong></p>
</div><p>Featured Image: DepositPhotos @ Capifrutta</p>
<div class="lb-trans"><p>特色图片：DepositPhotos @ Capifrutta</p>
</div><p>Disclaimer</p>
<div class="lb-trans"><p>免责声明</p>
</div><p>The post TransMedics Stock Plunges Post-Q3 Results appeared first on Invezz</p>
<div class="lb-trans"><p>本文转载自 Invezz</p>
</div>

TransMedics 股票在第三季度业绩公布后大幅下跌